Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 |
| clinicaltrials |
| NCT04971187 | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT02710396 | Genetic Predictors of Benefit to Pembrolizumab | terminated | Phase 2 | 19 | Columbia UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | terminated | Phase 2 | 8 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03805841 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions(RAIN) | terminated | Phase 2 | 41 | Rain Oncology IncINDUSTRY | 3 | Jun 28, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT04372927 | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | terminated | Phase 1 / Phase 2 | 46 | Nisha Mohindra, MDOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | terminated | Phase 2 | 24 | Wuhan UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 4 | Xencor, Inc.INDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04863248 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)(PRESERVE 4) | terminated | Phase 2 | 10 | G1 Therapeutics, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03030131 | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer(IONESCO) | terminated | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors(PROPEL) | terminated | Phase 1 / Phase 2 | 162 | Nektar TherapeuticsINDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT03838848 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 120 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03713944 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 30 | Nasser HannaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT04438902 | Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment | terminated | Phase 2 | 3 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | terminated | Phase 2 | 9 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02513667 | Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma | terminated | Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT02706626 | Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors | terminated | Phase 2 | 32 | Criterium, Inc.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT04297748 | Bioimaging Study of 89Zr-M7824 in NSCLC | terminated | Phase 1 / Phase 2 | 5 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02454842 | Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients(TH-4000) | terminated | Phase 2 | 21 | Rain Oncology IncINDUSTRY | 2 | Jan 12, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03661567 | Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer | terminated | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03784599 | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC(TRAEMOS) | terminated | Phase 2 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03430063 | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | terminated | Phase 2 | 28 | Regeneron PharmaceuticalsINDUSTRY | 9 | Nov 3, 2022 | clinicaltrials |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 22 | Ludwig Institute for Cancer ResearchOTHER | 5 | Oct 25, 2022 | clinicaltrials |
| NCT04634110 | Brigatinib Before Brain Irradiation Trial (B3i Trial) | terminated | Phase 2 | 1 | University of Colorado, DenverOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04398199 | Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients | terminated | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC(KEAPSAKE) | terminated | Phase 2 | 40 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 21, 2022 | clinicaltrials |
| NCT00754364 | Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients | terminated | Phase 2 | 108 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02967133 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | terminated | Phase 2 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | terminated | Phase 2 | 9 | Helix BioPharma CorporationINDUSTRY | 2 | Aug 12, 2022 | clinicaltrials |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | terminated | Phase 2 | 19 | WindMIL TherapeuticsINDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04560686 | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | terminated | Phase 2 | 3 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2023source: clinicaltrials